FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292336321> ?p ?o ?g. }

• W4292336321 endingPage "55" @default.
• W4292336321 startingPage "46" @default.
• W4292336321 abstract "Aims To describe glucose-lowering treatment regimens and glycated haemoglobin (HbA1c) trajectories in individuals with type 2 diabetes (T2D) over 36 months of follow-up from the start of second-line therapy. Materials and Methods This data analysis from the 3-year, observational DISCOVER study programme included 14 687 participants from 37 countries with T2D initiating second-line glucose-lowering therapy. Treatment and HbA1c data were collected at baseline (start of second-line therapy) and at 6, 12, 24 and 36 months. Treatment regimen changes over follow-up were analysed using the McNemar test, with carry-forward imputation for intermediate missing values. Results A total of 11 592 participants had treatment data at baseline and 36 months, and 11 882 had HbA1c data at baseline. At baseline and 36 months, respectively, rates of oral monotherapy use were 12.1% and 12.4% (P = 0.22), rates of dual oral therapy use were 63.4% and 47.6% (P < 0.0001), rates of ≥ triple oral therapy use were 17.5% and 25.4% (P < 0.0001), and rates of injectable treatment use were 7.0% and 13.7% (P < 0.0001). Use of injectable drugs was most common among participants with an HbA1c level ≥64 mmol/mol (≥8.0%). Overall, 42.9% of participants changed treatment during follow-up. Mean HbA1c levels at baseline and 6 months were 67 mmol/mol (8.3%) and 55 mmol/mol (7.2%), respectively, remaining stable thereafter. Conclusions Dual oral therapy was the most common treatment regimen at the start of second-line treatment, and over half of the participants remained on the same treatment during follow-up." @default.
• W4292336321 created "2022-08-19" @default.
• W4292336321 creator A5008251932 @default.
• W4292336321 creator A5010127891 @default.
• W4292336321 creator A5025169113 @default.
• W4292336321 creator A5036549660 @default.
• W4292336321 creator A5037246488 @default.
• W4292336321 creator A5042685051 @default.
• W4292336321 creator A5043895658 @default.
• W4292336321 creator A5048863829 @default.
• W4292336321 creator A5058016055 @default.
• W4292336321 creator A5064716875 @default.
• W4292336321 creator A5069970159 @default.
• W4292336321 creator A5083222970 @default.
• W4292336321 creator A5084153650 @default.
• W4292336321 creator A5084734229 @default.
• W4292336321 creator A5085417988 @default.
• W4292336321 creator A5090192766 @default.
• W4292336321 date "2022-09-16" @default.
• W4292336321 modified "2023-10-16" @default.
• W4292336321 title "Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global <scp>DISCOVER</scp> study" @default.
• W4292336321 cites W2047193384 @default.
• W4292336321 cites W2105744242 @default.
• W4292336321 cites W2150959326 @default.
• W4292336321 cites W2165825148 @default.
• W4292336321 cites W2328114764 @default.
• W4292336321 cites W2507901651 @default.
• W4292336321 cites W2594451671 @default.
• W4292336321 cites W2605094530 @default.
• W4292336321 cites W2763974796 @default.
• W4292336321 cites W2780718090 @default.
• W4292336321 cites W2795700244 @default.
• W4292336321 cites W2798054615 @default.
• W4292336321 cites W2888185938 @default.
• W4292336321 cites W2889089805 @default.
• W4292336321 cites W2894993577 @default.
• W4292336321 cites W2922745639 @default.
• W4292336321 cites W2960366561 @default.
• W4292336321 cites W3004838676 @default.
• W4292336321 cites W4235701932 @default.
• W4292336321 cites W4235767814 @default.
• W4292336321 cites W4292336321 @default.
• W4292336321 doi "https://doi.org/10.1111/dom.14842" @default.
• W4292336321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36111434" @default.
• W4292336321 hasPublicationYear "2022" @default.
• W4292336321 type Work @default.
• W4292336321 citedByCount "1" @default.
• W4292336321 countsByYear W42923363212022 @default.
• W4292336321 crossrefType "journal-article" @default.
• W4292336321 hasAuthorship W4292336321A5008251932 @default.
• W4292336321 hasAuthorship W4292336321A5010127891 @default.
• W4292336321 hasAuthorship W4292336321A5025169113 @default.
• W4292336321 hasAuthorship W4292336321A5036549660 @default.
• W4292336321 hasAuthorship W4292336321A5037246488 @default.
• W4292336321 hasAuthorship W4292336321A5042685051 @default.
• W4292336321 hasAuthorship W4292336321A5043895658 @default.
• W4292336321 hasAuthorship W4292336321A5048863829 @default.
• W4292336321 hasAuthorship W4292336321A5058016055 @default.
• W4292336321 hasAuthorship W4292336321A5064716875 @default.
• W4292336321 hasAuthorship W4292336321A5069970159 @default.
• W4292336321 hasAuthorship W4292336321A5083222970 @default.
• W4292336321 hasAuthorship W4292336321A5084153650 @default.
• W4292336321 hasAuthorship W4292336321A5084734229 @default.
• W4292336321 hasAuthorship W4292336321A5085417988 @default.
• W4292336321 hasAuthorship W4292336321A5090192766 @default.
• W4292336321 hasBestOaLocation W42923363211 @default.
• W4292336321 hasConcept C105795698 @default.
• W4292336321 hasConcept C126322002 @default.
• W4292336321 hasConcept C134018914 @default.
• W4292336321 hasConcept C186282968 @default.
• W4292336321 hasConcept C2776999253 @default.
• W4292336321 hasConcept C2777180221 @default.
• W4292336321 hasConcept C2777538456 @default.
• W4292336321 hasConcept C2779306644 @default.
• W4292336321 hasConcept C2780323712 @default.
• W4292336321 hasConcept C2781413609 @default.
• W4292336321 hasConcept C2909938374 @default.
• W4292336321 hasConcept C33923547 @default.
• W4292336321 hasConcept C555293320 @default.
• W4292336321 hasConcept C71924100 @default.
• W4292336321 hasConcept C90924648 @default.
• W4292336321 hasConceptScore W4292336321C105795698 @default.
• W4292336321 hasConceptScore W4292336321C126322002 @default.
• W4292336321 hasConceptScore W4292336321C134018914 @default.
• W4292336321 hasConceptScore W4292336321C186282968 @default.
• W4292336321 hasConceptScore W4292336321C2776999253 @default.
• W4292336321 hasConceptScore W4292336321C2777180221 @default.
• W4292336321 hasConceptScore W4292336321C2777538456 @default.
• W4292336321 hasConceptScore W4292336321C2779306644 @default.
• W4292336321 hasConceptScore W4292336321C2780323712 @default.
• W4292336321 hasConceptScore W4292336321C2781413609 @default.
• W4292336321 hasConceptScore W4292336321C2909938374 @default.
• W4292336321 hasConceptScore W4292336321C33923547 @default.
• W4292336321 hasConceptScore W4292336321C555293320 @default.
• W4292336321 hasConceptScore W4292336321C71924100 @default.
• W4292336321 hasConceptScore W4292336321C90924648 @default.
• W4292336321 hasFunder F4320307770 @default.
• W4292336321 hasIssue "1" @default.

• next